{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:01:11Z","timestamp":1780340471533,"version":"3.54.1"},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Multinational clinical trials are increasingly common in the European Economic Area, yet no guideline exists on which EQ-5D value set(s) should be used for health economic evaluations alongside multinational trials. Either a single value set or country-specific value sets can be applied, and previous studies have shown that the choice of value set can impact the estimated utility scores. For the EQ-5D-5L, the impact on European pooled cost-utility analyses has not been established. This study evaluates the impact of EQ-5D-5L value sets on cost-utility outcomes in two multinational trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from two multinational randomized controlled trials were used: (i) supervised exercise compared to usual care for patients with metastatic breast cancer (PREFERABLE-EFFECT), (ii) hemodiafiltration compared to hemodialysis for patients with kidney failure (CONVINCE). EQ-5D-5L was assessed at baseline and during follow-up. Utility scores and quality-adjusted life years (QALYs) were calculated with the country-specific value set for each participant, and with the value set of each included country. The probability of cost-effectiveness was estimated using bootstrapping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean assigned utility scores per year alive ranged between 0.762 and 0.889 for PREFERABLE-EFFECT, and 0.673 and 0.806 for CONVINCE. The difference in utility scores is largest when participants report low quality of life. Estimated QALY gains ranged between 0.013 and 0.020 for PREFERABLE-EFFECT and 0.045 and 0.058 for CONVINCE. The maximum difference in probability of cost-effectiveness between the value sets was \u03948.3% at \u20ac80,000\/QALY in PREFERABLE-EFFECT, and \u039411.1% at \u20ac40,000\/QALY for CONVINCE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Choice of value set led to substantial variation in absolute utility scores and QALYs, which may influence cost-utility outcomes. This impact could be greater when an intervention prevents or aids recovery of health conditions associated with low quality of life, or results in large mortality differences. Scenario analyses using multiple value sets should be conducted for multinational trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0350019","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:04:21Z","timestamp":1780337061000},"page":"e0350019","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Choice and impact of EQ-5D-5L value set in cost-utility analyses alongside multinational trials: Insights from PREFERABLE-EFFECT and CONVINCE"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8860-3823","authenticated-orcid":true,"given":"Aniek E. M.","family":"Schouten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert W. J.","family":"Frederix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn M.","family":"Stuiver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk E.","family":"Hiensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Cromm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Canaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni F. M.","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam P.","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the PREFERABLE-EFFECT Scientific Committee, and the CONVINCE Scientific Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"pone.0350019.ref001","first-page":"1","article-title":"The Development of the EQ-5D-5L and its Value Sets.","author":"N Devlin","year":"2022","journal-title":"Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide. Cham (CH): Springer"},{"issue":"6","key":"pone.0350019.ref002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131949","article-title":"Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies","volume":"10","author":"R Oppong","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0350019.ref003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1524-4733.2009.00582.x","article-title":"The multinational nature of cost-effectiveness analyses alongside multinational clinical trials","volume":"13","author":"O Rivero-Arias","year":"2010","journal-title":"Value Health"},{"issue":"3","key":"pone.0350019.ref004","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1017\/S0266462311000274","article-title":"Differences among formulary submission guidelines: implications for health technology assessment","volume":"27","author":"J Mauskopf","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"pone.0350019.ref005","article-title":"Qualitative comparative analysis of health economic evaluation guidelines for health technology assessment in European countries","volume":"37","author":"K Zisis","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"key":"pone.0350019.ref006","first-page":"213","article-title":"Guidance to Users of EQ-5D-5L Value Sets.","author":"N Devlin","year":"2022","journal-title":"Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide. Cham (CH): Springer"},{"issue":"6","key":"pone.0350019.ref007","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40273-018-0642-5","article-title":"A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D","volume":"36","author":"I Buchholz","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"pone.0350019.ref008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jval.2018.05.010","article-title":"Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol","volume":"22","author":"E Stolk","year":"2019","journal-title":"Value Health"},{"key":"pone.0350019.ref009","first-page":"13","article-title":"The Development and Strengthening of Methods for Valuing EQ-5D-5L \u2013 An Overview.","author":"E Stolk","year":"2022","journal-title":"Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide. Cham (CH): Springer"},{"key":"pone.0350019.ref010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-3-030-89289-0_6","article-title":"How Do EQ-5D-5L Value Sets Differ?.","author":"B Roudijk","year":"2022","journal-title":"Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide"},{"issue":"4","key":"pone.0350019.ref011","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report","volume":"12","author":"M Drummond","year":"2009","journal-title":"Value Health"},{"key":"pone.0350019.ref012","unstructured":"IQVIA, European Federation of Pharmaceutical Industries and Associations, Vaccines Europe. Assessing the clinical trial ecosystem in Europe. 2024. Accessed January 12, 2025. https:\/\/efpia.eu\/media\/3edpooqp\/assessing-the-clinical-trial-ecosystem-in-europe.pdf"},{"issue":"3","key":"pone.0350019.ref013","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ahj.2004.11.001","article-title":"Conducting economic evaluations alongside multinational clinical trials: toward a research consensus","volume":"149","author":"SD Reed","year":"2005","journal-title":"Am Heart J"},{"issue":"5","key":"pone.0350019.ref014","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/hec.914","article-title":"Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models","volume":"14","author":"A Manca","year":"2005","journal-title":"Health Econ"},{"issue":"12","key":"pone.0350019.ref015","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2165\/11537760-000000000-00000","article-title":"The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions","volume":"28","author":"A Manca","year":"2010","journal-title":"PharmacoEconomics"},{"issue":"2","key":"pone.0350019.ref016","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10198-011-0360-9","article-title":"The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough\/lower respiratory tract infections in seven countries","volume":"14","author":"R Oppong","year":"2013","journal-title":"Eur J Health Econ"},{"issue":"1","key":"pone.0350019.ref017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12874-022-01830-3","article-title":"In search of a \u201cpan-European value set\u201d; application for EQ-5D-3L","volume":"23","author":"A Sajjad","year":"2023","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"pone.0350019.ref018","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hec.3606","article-title":"In search of a common currency: A comparison of seven EQ-5D-5L value sets","volume":"27","author":"JA Olsen","year":"2018","journal-title":"Health Econ"},{"issue":"12","key":"pone.0350019.ref019","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40273-022-01194-y","article-title":"Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments","volume":"40","author":"A \u0141aszewska","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"pone.0350019.ref020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","article-title":"A single European currency for EQ-5D health states. Results from a six-country study","volume":"4","author":"W Greiner","year":"2003","journal-title":"Eur J Health Econ"},{"issue":"34","key":"pone.0350019.ref021","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007840","article-title":"Does the choice of tariff matter?: A comparison of EQ-5D-5L utility scores using Chinese, UK, and Japanese tariffs on patients with psoriasis vulgaris in Central South China","volume":"96","author":"Y Zhao","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"pone.0350019.ref022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13104-019-4067-9","article-title":"Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results","volume":"12","author":"C Gerlinger","year":"2019","journal-title":"BMC Res Notes"},{"issue":"1","key":"pone.0350019.ref023","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MLR.0000000000001417","article-title":"Assessing the Impact of EQ-5D Country-specific Value Sets on Cost-utility Outcomes","volume":"59","author":"JM van Dongen","year":"2021","journal-title":"Med Care"},{"issue":"5","key":"pone.0350019.ref024","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1524-4733.2009.00509.x","article-title":"Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries","volume":"12","author":"S Bernert","year":"2009","journal-title":"Value Health"},{"issue":"12","key":"pone.0350019.ref025","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1136\/ard.2011.153437","article-title":"National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients","volume":"70","author":"JA Karlsson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"pone.0350019.ref026","doi-asserted-by":"crossref","first-page":"100165","DOI":"10.1016\/j.lanepe.2021.100165","article-title":"Properties of the EQ-5D-5L when prospective longitudinal data from 28,902 total hip arthroplasty procedures are applied to different European EQ-5D-5L value sets","volume":"8","author":"A Joelson","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"pone.0350019.ref027","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12955-015-0344-z","article-title":"Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients","volume":"13","author":"AA Kiadaliri","year":"2015","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"pone.0350019.ref028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00005650-200503000-00004","article-title":"Valuations of EQ-5D health states: are the United States and United Kingdom different?","volume":"43","author":"JA Johnson","year":"2005","journal-title":"Med Care"},{"issue":"6","key":"pone.0350019.ref029","doi-asserted-by":"crossref","DOI":"10.3747\/co.22.2592","article-title":"Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer","volume":"22","author":"K Lien","year":"2015","journal-title":"Curr Oncol"},{"issue":"6","key":"pone.0350019.ref030","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s11136-007-9206-4","article-title":"US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?","volume":"16","author":"I-C Huang","year":"2007","journal-title":"Qual Life Res"},{"key":"pone.0350019.ref031","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10198-019-01069-8","article-title":"A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases","volume":"20","author":"Z Zrubka","year":"2019","journal-title":"Eur J Health Econ"},{"issue":"4","key":"pone.0350019.ref032","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.kint.2024.12.018","article-title":"A health economic evaluation of the multinational, randomized controlled CONVINCE trial: cost-utility of high-dose online hemodiafiltration compared to high-flux hemodialysis","volume":"107","author":"AEM Schouten","year":"2025","journal-title":"Kidney Int"},{"key":"pone.0350019.ref033","article-title":"Supervised exercise for patients with metastatic breast cancer: a cost-utility analysis alongside the PREFERABLE-EFFECT randomized controlled trial","author":"AEM Schouten","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0350019.ref034","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s13063-022-06556-7","article-title":"Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study","volume":"23","author":"AE Hiensch","year":"2022","journal-title":"Trials"},{"issue":"10","key":"pone.0350019.ref035","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1038\/s41591-024-03143-y","article-title":"Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial","volume":"30","author":"AE Hiensch","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"pone.0350019.ref036","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033228","article-title":"Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol","volume":"10","author":"PJ Blankestijn","year":"2020","journal-title":"BMJ Open"},{"issue":"8","key":"pone.0350019.ref037","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJMoa2304820","article-title":"Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure","volume":"389","author":"PJ Blankestijn","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0350019.ref038","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s12913-021-06513-1","article-title":"The statistical approach in trial-based economic evaluations matters: get your statistics together!","volume":"21","author":"EN Mutubuki","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"pone.0350019.ref039","first-page":"1","article-title":"Mice: Multivariate imputation by chained equations in R","volume":"45","author":"S van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"pone.0350019.ref040","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","article-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987"},{"issue":"6","key":"pone.0350019.ref041","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","article-title":"German Value Set for the EQ-5D-5L","volume":"36","author":"K Ludwig","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"pone.0350019.ref042","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch Tariff for the Five-Level Version of EQ-5D","volume":"19","author":"M M Versteegh","year":"2016","journal-title":"Value Health"},{"issue":"5","key":"pone.0350019.ref043","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","article-title":"Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach","volume":"21","author":"JM Ramos-Go\u00f1i","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"pone.0350019.ref044","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12955-022-02083-w","article-title":"Estimating a social value set for EQ-5D-5L in Sweden","volume":"20","author":"S Sun","year":"2022","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"pone.0350019.ref045","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s40273-019-00811-7","article-title":"Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe","volume":"37","author":"D Golicki","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"pone.0350019.ref046","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40273-023-01243-0","article-title":"The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia","volume":"41","author":"R Norman","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"pone.0350019.ref047","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s11136-019-02226-5","article-title":"A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set","volume":"28","author":"PL Ferreira","year":"2019","journal-title":"Qual Life Res"},{"key":"pone.0350019.ref048","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jval.2020.03.019","article-title":"Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary","volume":"23","author":"F Rencz","year":"2020","journal-title":"Value in Health"},{"issue":"4","key":"pone.0350019.ref049","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40273-019-00876-4","article-title":"A French Value Set for the EQ-5D-5L","volume":"38","author":"LF Andrade","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"pone.0350019.ref050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10198-022-01481-7","article-title":"EQ-5D-5L: a value set for Romania","volume":"24","author":"E Olariu","year":"2023","journal-title":"Eur J Health Econ"},{"issue":"11","key":"pone.0350019.ref051","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"P Dolan","year":"1997","journal-title":"Med Care"},{"issue":"5","key":"pone.0350019.ref052","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"B van Hout","year":"2012","journal-title":"Value Health"},{"key":"pone.0350019.ref053","author":"M van Reenen","year":"2019"},{"key":"pone.0350019.ref054","unstructured":"National Institute for Health and Care Excellence (NICE). Position statement on use of the EQ-5D-5L value set for England (updated October 2019). Accessed April 29, 2025. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/technology-appraisal-guidance\/eq-5d-5l"},{"key":"pone.0350019.ref055","article-title":"A UK value set for the EQ-5D-5L","author":"D Rowen","year":"2026","journal-title":"Value in Health"},{"key":"pone.0350019.ref056","unstructured":"National Institute for Health and Care Excellence (NICE). Have your say on NICE\u2019s adoption of the new EQ-5D-5L value set (updated 2026 Apr 15). Accessed April 17, 2026. Available from: https:\/\/www.nice.org.uk\/news\/articles\/have-your-say-on-nices-adoption-of-the-new-eq-5d-5l-value-set"},{"key":"pone.0350019.ref057","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"MF Drummond","year":"2015","edition":"4"},{"issue":"11","key":"pone.0350019.ref058","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s40273-023-01301-7","article-title":"Conducting Trial-Based Economic Evaluations Using R: A Tutorial","volume":"41","author":"\u00c2J Ben","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"pone.0350019.ref059","author":"Zorginstituut Nederland","year":"2015"},{"key":"pone.0350019.ref060","article-title":"Bootstrap Methods: With Applications in R","author":"G Dikta","year":"2021","journal-title":"Cham: Springer Nature Switzerland AG"},{"issue":"5","key":"pone.0350019.ref061","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0272989X19841587","article-title":"Cultural Values: Can They Explain Differences in Health Utilities between Countries?","volume":"39","author":"B Roudijk","year":"2019","journal-title":"Med Decis Making"},{"key":"pone.0350019.ref062","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-6-71","article-title":"A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes","volume":"6","author":"P Sakthong","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"pone.0350019.ref063","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report","volume":"22","author":"J Brazier","year":"2019","journal-title":"Value Health"},{"key":"pone.0350019.ref064","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.jval.2023.08.005","article-title":"UK valuation of EQ-5D-5L, a generic measure of health-related quality of life: a study protocol","volume":"26","author":"D Rowen","year":"2023","journal-title":"Value in Health"},{"issue":"5","key":"pone.0350019.ref065","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40273-025-01476-1","article-title":"A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete","volume":"43","author":"R Norman","year":"2025","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"pone.0350019.ref066","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s11136-014-0864-8","article-title":"Cross-cultural measurement equivalence of the EQ-5D-5L items for English-speaking Asians in Singapore","volume":"24","author":"N Luo","year":"2015","journal-title":"Qual Life Res"},{"issue":"1","key":"pone.0350019.ref067","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jval.2015.10.010","article-title":"Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study","volume":"19","author":"A Hayes","year":"2016","journal-title":"Value Health"},{"issue":"10","key":"pone.0350019.ref068","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/MLR.0b013e3182239489","article-title":"Comparability of patient-reported health status: multicountry analysis of EQ-5D responses in patients with type 2 diabetes","volume":"49","author":"JA Salomon","year":"2011","journal-title":"Med Care"},{"issue":"18","key":"pone.0350019.ref069","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1212\/WNL.0b013e3182a9f45f","article-title":"Quality of life after TIA and stroke","volume":"81","author":"R Luengo-Fernandez","year":"2013","journal-title":"Neurology"},{"issue":"9","key":"pone.0350019.ref070","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/11314120-000000000-00000","article-title":"Utilities of the EQ-5D: transferable or not?","volume":"27","author":"S Knies","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"pone.0350019.ref071","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/jmahp13040052","article-title":"EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making","volume":"13","author":"A Johns","year":"2025","journal-title":"J Mark Access Health Policy"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:04:31Z","timestamp":1780337071000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350019"}},"subtitle":[],"editor":[{"given":"Henry Hugh","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":71,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0350019","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}